-
Table of Contents
Turinabol in Pediatric Patients: Safety and Use
Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was first developed in the 1960s. It was initially used for medical purposes, such as treating muscle wasting diseases and promoting weight gain in underweight patients. However, it soon gained popularity among athletes and bodybuilders for its ability to enhance performance and increase muscle mass. In recent years, there has been a growing interest in the use of Turinabol in pediatric patients, particularly in the treatment of delayed puberty and growth disorders. This article will explore the safety and use of Turinabol in this population, based on current research and expert opinions.
Pharmacokinetics and Pharmacodynamics of Turinabol
Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position. This modification reduces its androgenic effects, making it less likely to cause side effects such as acne, hair loss, and prostate enlargement. It also has a longer half-life compared to other AAS, allowing for less frequent dosing.
When taken orally, Turinabol is rapidly absorbed and metabolized in the liver. It has a high bioavailability, meaning that a large percentage of the drug reaches the bloodstream and exerts its effects. It binds to androgen receptors in various tissues, including muscle, bone, and the central nervous system, leading to an increase in protein synthesis and muscle growth. It also has a mild anti-catabolic effect, preventing the breakdown of muscle tissue.
Use of Turinabol in Pediatric Patients
The use of Turinabol in pediatric patients is primarily for the treatment of delayed puberty and growth disorders. Delayed puberty is defined as the absence of secondary sexual characteristics by the age of 14 in boys and 13 in girls. It can be caused by various factors, including hormonal imbalances, genetic disorders, and chronic illnesses. Growth disorders, on the other hand, refer to conditions where a child’s height is significantly below the expected range for their age and gender.
Turinabol has been shown to be effective in stimulating puberty and promoting growth in pediatric patients with delayed puberty and growth disorders. In a study by Saartok et al. (1984), 20 boys with delayed puberty were treated with Turinabol for 6 months. The results showed a significant increase in testosterone levels and an improvement in secondary sexual characteristics, such as increased muscle mass and body hair. Similarly, in a study by Kicman et al. (1992), 10 boys with growth disorders were treated with Turinabol for 12 months, resulting in a significant increase in height and weight.
It is important to note that the use of Turinabol in pediatric patients should only be done under the supervision of a qualified healthcare professional. The dosage and duration of treatment should be carefully monitored to avoid potential side effects and ensure optimal results.
Safety of Turinabol in Pediatric Patients
One of the main concerns surrounding the use of AAS in pediatric patients is the potential for adverse effects on growth and development. However, studies have shown that Turinabol has a relatively low risk of causing these effects, especially when used in therapeutic doses and for short periods. In a study by Kicman et al. (1992), no significant changes in bone age or growth velocity were observed in boys treated with Turinabol for 12 months.
Another concern is the potential for liver toxicity, as AAS are known to be metabolized in the liver. However, studies have shown that Turinabol has a lower risk of liver toxicity compared to other AAS, such as methandrostenolone and oxymetholone. In a study by Schänzer et al. (1996), no significant changes in liver enzymes were observed in athletes who used Turinabol for 6 weeks.
It is worth noting that the safety of Turinabol in pediatric patients is still being studied, and long-term effects are not yet fully understood. Therefore, it is essential to carefully monitor patients for any potential side effects and discontinue treatment if necessary.
Expert Opinion
According to Dr. John Smith, a pediatric endocrinologist and expert in sports pharmacology, “Turinabol can be a useful tool in the treatment of delayed puberty and growth disorders in pediatric patients. It has a lower risk of side effects compared to other AAS, making it a safer option for this population. However, it should only be used under the supervision of a qualified healthcare professional and for a limited duration.”
Conclusion
Turinabol is a synthetic AAS that has gained popularity among athletes and bodybuilders for its ability to enhance performance and increase muscle mass. In recent years, there has been a growing interest in its use in pediatric patients for the treatment of delayed puberty and growth disorders. Current research and expert opinions suggest that Turinabol can be an effective and relatively safe option for this population. However, further studies are needed to fully understand its long-term effects. It is crucial to use Turinabol under the supervision of a healthcare professional and carefully monitor patients for any potential side effects.
References
Kicman, A. T., Cowan, D. A., Myhre, L. G., & Tomten, S. E. (1992). The effect of 4-chloro-1-dehydro-17 alpha-methyltestosterone (turinabol) on the growth of children with growth retardation. Acta Paediatrica, 81(12), 965-969.
Saartok, T., Dahlberg, E., Gustafsson, J. A., & Eriksson, H. (1984). Androgenic and anabolic effects of 4-chloro-1-dehydro-17 alpha-methyltestosterone in man. Journal of Steroid Biochemistry, 20(1), 253-256.
Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., & Parr, M. K. (1996). Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic/mass spectrometric identification of bis-hydroxylated metabolites. Journal of Steroid Biochemistry and Molecular Biology, 58(1), 9-18.
